Navigation Links
Therapy combining exercise and neuroprotective agent shows promise for stroke victims

Amsterdam, NL, August 15, 2012 In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity.

"In our study, GSNO or motor exercise provided neuroprotection, reduced neuronal cell death, maintained tissue structure, and aided functional recovery by stimulating the expression of neuronal repair mediators," says lead investigator Avtar K. Singh, MD, of the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center, Charleston. "GSNO in combination with exercise accelerated the rate and enhanced the degree of recovery."

Stroke is both an acute disease and a chronic condition. While the acute phase is associated with cell death and secondary injury, the chronic phase is characterized by insufficient neurorepair mechanisms. Most monotherapies fail because the drugs are not effective in the chronic phase. Rehabilitation has been used to improve neurofunction in the chronic phase, but its efficacy is slow and limited. An ideal therapy would ameliorate the injury in both phases and therefore include a combination of rehabilitation and an agent that provides both neuroprotection and repair, such as GSNO.

Dr. Singh and her colleagues from MUSC (Drs. Mushfiquddin Khan, Harutoshi Sakakima and Inderjit Singh) induced stroke in rats, which were then assigned to one of five treatment groups. The first group received no treatment; the second group was treated with exercise; the third group with GSNO; the fourth group received both exercise and GSNO treatment; and the fifth group received a sham treatment. In the exercise treatment, rats were required to run on a rotating rod motor unit at a constant speed for 20 minutes a day. GSNO was administered throughout the treatment period.

Animals in each group were evaluated for neurological function, motor behavior, and locomotor function before and after the procedure. The size of the infarct was measured. At 7 and 14 days after stroke was induced, brain tissue samples were removed and tested.

Administration of GSNO not only reduced brain injury but also improved neurological scores. Exercise alone could not significantly reduce infarct volume, because the exercise started 72 hours post procedure and infarctions occur before then. However, exercise did improve neurobehavioral functions. Combining the therapies had a synergistic effect, and provided greater functional improvement than either GSNO or exercise alone.

Analysis of the brain tissue found that GSNO accelerates the recovery of neurological and motor functions and enhances the benefit of exercise by stimulating the expression of neurotrophic factor BDNF and its receptors, which play critical roles in neurorepair processes, and by activating Akt, a protein involved in cell proliferation. Dr. Singh and her collaborators Drs. Mushfiquddin Khan and Inderjit Singh conclude, "GSNO is an attractive candidate to be investigated in humans for neurorepair and rehabilitation following stroke."


Contact: Daphne Watrin
IOS Press

Related medicine news :

1. Couples Therapy May Help Combat PTSD
2. CNIO researchers discover a new therapy that prevents lung cancer growth in mice
3. 7-Day Stuttering Therapy May Get Results, Study Says
4. Tourette Patients Benefit From Behavioral Therapy: Study
5. Adalimumab is a promising therapy for children with Crohns disease
6. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
7. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
8. Standard radiation therapy dose provides pain relief for painful heel spurs
9. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
10. Telephone therapy technique brings more Iraq and Afghanistan veterans into mental health treatment
11. Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy
Post Your Comments:
Related Image:
Therapy combining exercise and neuroprotective agent shows promise for stroke victims
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
(Date:11/24/2015)... ... 24, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy ... regardless of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... Ontario , Nov. 24, 2015 Teledyne ... digital X-Ray image sensing technology, will introduce its CMOS ... Technical Exhibition , November 29 to December 3, at McCormick ... of dynamic detectors for diagnostic and interventional imaging will be ... Xineos family of advanced CMOS X-Ray detectors is ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for ... growth to 2021, says GBI Research . ... Type 1 Diabetes Mellitus (T1DM), will be a key driver of market ... --> The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ...
Breaking Medicine Technology: